The role of pimecrolimus cream 1% (Elidel®) in managing adult atopic eczema

Dermatology

Volumn 215, Issue SUPPL. 1, 2007, Pages 18-26

  Meurer, Michael ^a   Lübbe, Jann ^b   Kapp, Alexander ^c   Schneider, Dirk ^d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b HUG   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atopic eczema; Disease management; Pimecrolimus; Topical calcineurin inhibitor

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE ACETATE; PIMECROLIMUS; TACROLIMUS; TRIAMCINOLONE ACETONIDE;

APPLICATION SITE BURNING; ATOPIC DERMATITIS; BODY SURFACE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FACE; HUMAN; LONG TERM CARE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SKIN INFECTION; TREATMENT DURATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; CALCINEURIN; DERMATITIS, ATOPIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SKIN; SKIN ABSORPTION; TACROLIMUS;

EID: 37349091237     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000102117     Document Type: Review

References (46)

1. Lawson V, Lewis-Jones MS, Finlay AY, Reid P, Owens RG: The family impact of childhood atopic dermatitis: the Dermatitis Family Impact Questionnaire. Br J Dermatol 1998;138:107-113.
2. Correale CE, Walker C, Murphy L, Craig TJ: Atopic dermatitis: a review of diagnosis and treatment. Am Fam Physician 1999;60:1191-1198, 1209-1210.
3. Spergel JM, Paller AS: Atopic dermatitis and the atopic march. J Allergy Clin Immunol 2003;112:S118-S127.
4. Kissling S, Wuthrich B: [Follow-up of atopic dermatitis after early childhood]. Hautarzt 1993;44:569-573.
5. Schultz-Larsen F, Hanifin J: Epidemiology of atopic dermatitis. Immunol Allergy Clin North Am 2002;22:1-24.
6. Montnemery P, Nihlen U, Goran Lofdahl C, Nyberg P, Svensson A: Prevalence of self-reported eczema in relation to living environment, socio-economic status and respiratory symptoms assessed in a questionnaire study. BMC Dermatol 2003;3:4.
7. Anderson RT, Rajagopalan R: Effects of allergic dermatosis on health-related quality of life. Curr Allergy Asthma Rep 2001;1:309-315.
8. Eichenfield LF, Hanifin JM, Beck LA, Lemanske RF Jr, Sampson HA, Weiss ST, Leung DY: Atopic dermatitis and asthma: parallels in the evolution of treatment. Pediatrics 2003;111:608-616.
9. Novak N, Bieber T, Leung DY: Immune mechanisms leading to atopic dermatitis. J Allergy Clin Immunol 2003;112:S128-S139.
10. Mittermann I, Aichberger KJ, Bunder R, Mothes N, Renz H, Valenta R: Autoimmunity and atopic dermatitis. Curr Opin Allergy Clin Immunol 2004;4:367-371.
11. Linnet J, Jemec GB: An assessment of anxiety and dermatology life quality in patients with atopic dermatitis. Br J Dermatol 1999;140:268-272.
12. Linnet J, Jemec GB: Anxiety level and severity of skin condition predicts outcome of psychotherapy in atopic dermatitis patients. Int J Dermatol 2001;40:632-636.
13. Schiffner R, Schiffner-Rohe J, Landthaler M, Stolz W: Treatment of atopic dermatitis and impact on quality of life: a review with emphasis on topical non-corticosteroids. Pharmacoeconomics 2003;21:159-179.
14. Fivenson D, Arnold RJ, Kaniecki DJ, Cohen JL, Frech F, Finlay AY: The effect of atopic dermatitis on total burden of illness and quality of life on adults and children in a large managed care organization. J Manag Care Pharm 2002;8:333-342.
15. Abeck D, Strom K: Optimal management of atopic dermatitis. Am J Clin Dermatol 2000;1:41-46.
16. Hepburn D, Yohn JJ, Weston WL: Topical steroid treatment in infants, children, and adolescents. Adv Dermatol 1994;9:225-255.
17. Leung DY, Hanifin JM, Charlesworth EN, Li JT, Bernstein IL, Berger WE, Blessing-Moore J, Fineman S, Lee FE, Nicklas RA, Spector SL: Disease management of atopic dermatitis: a practice parameter. Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology, the American College of Allergy, Asthma and Immunology, and the Joint Council of Allergy, Asthma and Immunology. Work Group on Atopic Dermatitis. Ann Allergy Asthma Immunol 1997;79:197-211.
18. Ellis C, Luger T, Abeck D, Allen R, Graham-Brown RA, De Prost Y, Eichenfield LF, Ferrandiz C, Giannetti A, Hanifin J, Koo JY, Leung D, Lynde C, Ring J, Ruiz-Maldonado R, Saurat JH: International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies. Br J Dermatol 2003;148(suppl 63):3-10.
19. Charman CR, Morris AD, Williams HC: Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000;142:931-936.
20. Hill CJ, Rostenberg A Jr: Adverse effects from topical steroids. Cutis 1978;21:624-628.
21. Lapsley P: Itching for a solution. BMJ 2005;330:522.
22. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS: Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association 'Administrative Regulations for Evidence-Based Clinical Practice Guidelines'. J Am Acad Dermatol 2004;50:391-404.
23. Simon D, Lubbe J, Wuthrich B, Wiesner A, Weber MM, Laffitte E, Anliker MD, Schoni MH, Braathen LR, Schmid-Grendelmeier P, Gilgen Bobali N, Schneider D: Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Analysis of a Swiss cohort. Dermatology 2006;213:313-318.
24. Reitamo S, Ortonne JP, Sand C, Cambazard F, Bieber T, Folster-Holst R, Vena G, Bos JD, Fabbri P, Groenhoej Larsen C: A multicentre, randomized, double-blind, controlled study of long-term treatment with 0.1% tacrolimus ointment in adults with moderate to severe atopic dermatitis. Br J Dermatol 2005;152:1282-1289.
25. Reitamo S, Rustin M, Ruzicka T, Cambazard F, Kalimo K, Friedmann PS, Schoepf E, Lahfa M, Diepgen TL, Judodihardjo H, Wollenberg A, Berth-Jones J, Bieber T: Efficacy and safety of tacrolimus ointment compared with that of hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J Allergy Clin Immunol 2002;109:547-555.
26. Meurer M, Folster-Holst R, Wozel G, Weidinger G, Junger M, Brautigam M: Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six-month study. Dermatology 2002;205:271-277.
27. Kaufmann R, Bieber T, Helgesen AL, Andersen BL, Luger T, Poulin Y, Al-Hafidh J, Paul C: Onset of pruritus relief with pimecrolimus cream 1% in adult patients with atopic dermatitis: a randomized trial. Allergy 2006;61:375-381.
28. Meurer M, Fartasch M, Albrecht G, Vogt T, Worm M, Ruzicka T, Altmeyer PJ, Schneider D, Weidinger G, Braeutigam M, For The CASM-DE. Study Group: Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis. Dermatology 2004;208:365-372.
29. Eichenfield LF, Lucky AW, Boguniewicz M, Langley RG, Cherill R, Marshall K, Bush C, Graeber M: Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. J Am Acad Dermatol 2002;46:495-504.
30. Luger T, Lahfa M, Folster-Holst R, Gulliver W, Allen R, Molloy S, Barbier N, Paul C, Bos JD: Long-term safety and tolerability of pimecrolimus cream 1% and topical corticosteroids in adults with moderate to severe atopic dermatitis. J Dermatolog Treat 2004;15:1-10.
31. Whalley D, McKenna SP, Dewar AL, Erdman RA, Kohlmann T, Niero M, Cook SA, Crickx B, Herdman MJ, Frech F, Van Assche D: A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004;150:274-283.
32. Schürmeyer-Horst F, Luger TA, Böhm M: Long-term efficacy of occlusive therapy with topical pimecrolimus in severe dyshidrosiform hand and foot eczema. Dermatology 2007;214:99-100.
33. Billich A, Aschauer H, Aszodi A, Stuetz A: Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus. Int J Pharm 2004;269:29-35.
34. Van Leent EJ, Ebelin ME, Burtin P, Dorobek B, Spuls PI, Bos JD: Low systemic exposure after repeated topical application of pimecrolimus (Elidel, SDZ ASM 981) in patients with atopic dermatitis. Dermatology 2002;204:63-68.
35. Draelos Z, Nayak A, Pariser D, Shupack JL, Chon K, Abrams B, Paul CF: Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison. J Am Acad Dermatol 2005;53:602-609.
36. Oji V, Beljan G, Beier K, Traupe H, Luger TA: Topical pimecrolimus: a novel therapeutic option for Netherton syndrome. Br J Dermatol 2005;153:1067-1068.
37. Allen A, Siegfried E, Silverman R, Williams ML, Elias PM, Szabo SK, Korman NJ: Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 2001;137:747-750.
38. Allen DM, Esterly NB: Significant systemic absorption of tacrolimus after topical application in a patient with lamellar ichthyosis. Arch Dermatol 2002;138:1259-1260.
39. Queille-Roussel C, Paul C, Duteil L, Lefebvre MC, Rapatz G, Zagula M, Ortonne JP: The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001;144:507-513.
40. Furue M, Terao H, Rikihisa W, Urabe K, Kinukawa N, Nose Y, Koga T: Clinical dose and adverse effects of topical steroids in daily management of atopic dermatitis. Br J Dermatol 2003;148:128-133.
41. Bonifazi E, Garofalo L, Pisani V, Meneghini CL: Role of some infectious agents in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985;114:98-100.
42. David TJ, Cambridge GC: Bacterial infection and atopic eczema. Arch Dis Child 1986;61:20-23.
43. Lubbe J: Secondary infections in patients with atopic dermatitis. Am J Clin Dermatol 2003;4:641-654.
44. Abeck D, Mempel M: Staphylococcus aureus colonization in atopic dermatitis and its therapeutic implications. Br J Dermatol 1998;139(suppl 53):13-16.
45. Rystedt I, Strannegard IL, Strannegard O: Recurrent viral infections in patients with past or present atopic dermatitis. Br J Dermatol 1986;114:575-582.
46. Strannegard O, Strannegard IL, Rystedt I: Viral infections in atopic dermatitis. Acta Derm Venereol Suppl (Stockh) 1985;114:121-124.